建立无症状1型糖尿病筛查项目:糖尿病照护人员的实用指南
1型糖尿病(T1D)有2个无症状阶段(1期和2期)先于临床发病(3期),其特征为可被自身抗体筛查Panel可靠检出的循环自身抗体。识别无症状阶段T1D人群可监测并预防糖尿病酮症酸中毒;一种已被证明可延缓3期T1D发病的疾病修饰疗法现已可用于2期患者,凸显早期检测的重要性。本报告为内分泌科医生提供在其诊所、机构、医疗网络和/或社区内建立临床自身抗体筛查项目的实践指导,包括提名项目负责人、组建实施团队、激励其他医生参与、标准化筛查流程中的沟通、工作流整合与物流简化等步骤,并需制定结果解读与沟通计划及后续随访保障。文中还讨论了筛查的常见障碍并提供了促进筛查项目采纳与成功的实用解决方案。
要点
- 1型糖尿病存在2个无症状阶段(1期和2期),可通过自身抗体筛查Panel可靠检出,先于临床发病(3期)。
- 识别无症状阶段T1D可监测并预防糖尿病酮症酸中毒,且一种疾病修饰疗法已可用于2期患者以延缓3期发病。
- 建立筛查项目需提名项目负责人、组建实施团队、激励其他医生参与,并标准化沟通、工作流整合与物流等步骤。
核心结论
- 需要更新指导与方案以将自身抗体筛查整合到标准实践中。
- 本报告为内分泌科医生提供在诊所、机构、医疗网络和/或社区内建立临床自身抗体筛查项目的指导。
- 识别无症状阶段T1D可监测并预防糖尿病酮症酸中毒,且一种疾病修饰疗法已被证明可延缓3期T1D发病并现已可用于2期患者。
研究设计与样本
- 本报告为针对内分泌科医生的指导性报告,提供建立临床自身抗体筛查项目的实践指导。
主要发现
- 1型糖尿病为自身免疫病,有2个无症状阶段(1期和2期)先于临床发病(3期)。
- 无症状阶段T1D的特征为循环自身抗体,可被自身抗体筛查Panel可靠检出。
- 一种疾病修饰疗法已被证明可延缓3期T1D发病,现已可用于2期患者。
- 建立筛查项目的关键步骤包括提名项目负责人、组建实施团队和激励其他医生参与。
- 实施筛查需标准化沟通、工作流整合与物流(如自身抗体Panel的订购与编码)等步骤,并制定结果解读、沟通与后续随访计划。
关键数值与推荐
- 1型糖尿病分为2个无症状阶段(1期和2期)和临床发病阶段(3期)。
- 无症状阶段以循环自身抗体为特征,可通过自身抗体筛查Panel可靠检出。
- 一种疾病修饰疗法已被证明可延缓3期T1D发病,现已可用于2期患者。
临床怎么用
- 内分泌科医生可在其诊所、机构、医疗网络和/或社区内建立临床自身抗体筛查项目。
- 建立筛查项目需提名项目负责人、组建实施团队并激励其他医生参与。
- 实施筛查需标准化与风险个体的沟通、将筛查整合到现有工作流、简化自身抗体Panel的订购与编码等物流。
- 医生必须制定结果解读与沟通计划,并确保个体未来可被适当随访。
- 文中讨论了筛查的常见障碍并提供了促进筛查项目采纳与成功的实用解决方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type 1 diabetes (T1D) is an autoimmune disease with 2 presymptomatic stages (stages 1 and 2) that precede its clinical onset (stage 3). The presymptomatic stages of T1D are characterized by circulating autoantibodies that can be reliably detected by autoantibody screening panels. Identifying people in the presymptomatic stages of T1D can allow for monitoring and prevention of diabetic ketoacidosis. A disease-modifying therapy that has been shown to delay onset of stage 3 T1D is now also available for individuals with stage 2 disease, highlighting the importance of early detection. This intervention may delay the onset of stage 3 T1D. Updated guidance and protocols are needed to integrate autoantibody screening into standard practice. This report provides guidance for endocrinology providers on establishing clinical autoantibody screening programs within their practices, institutions, healthcare networks, and/or communities. Key steps include nominating a champion for the program, building a team to implement screening, and motivating other providers to participate. Implementation of screening requires standardizing several steps in the screening process, including communicating with individuals at risk, integrating screening into existing workflows, and streamlining logistics such as ordering and coding for autoantibody panels. Providers must have a plan to interpret and communicate results and to ensure that individuals may be appropriately followed in the future. Here, common barriers to screening are addressed, and practical solutions to facilitate the adoption and success of screening initiatives are offered.
引用
- Leichter SB, Felton JL, Geno Rasmussen C, et al. Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers. J Clin Endocrinol Metab. 2025. PMID: 40171881. doi:10.1210/clinem/dgaf194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。